AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS Read more about AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) Read more about AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE Read more about AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE
AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND Read more about AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE Read more about AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC Read more about AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS Read more about AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE Read more about AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN Read more about TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST Read more about AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST
